Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
|Videos|January 3, 2018
Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy
Author(s)Jesús Berdeja, MD
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
Advertisement
Jesus Berdeja, MD, director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses a study of bb2121, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy.
The CAR T product bb2121 is for patients with relapsed or refractory multiple myeloma. In a phase I dose-escalation study, 24 patients were collected, and 21 patients were infused with the CAR T cell. Considering that this is a heavily pretreated population, Berdeja says that the number of patients infused was impressive.
Advertisement
Related to this article
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5